title: High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma.
abstract: Periostin (PN) is a kind of secreted glycoprotein, which is closely related to the metastatic potential and prognosis of many kinds of tumors in recent studies. However, the expression level of PN in hepatocellular carcinoma (HCC) and its correlation with tumor angiogenesis and prognosis remain unclear. Here Immunohistochemistry assay was used to determine the expression of PN in HCC and corresponding adjacent tissues from 71 patients. VEGF and CD34 were only examined in HCC tissues of patients mentioned above. Immunohistochemically, the expression of PN in HCC was judged to be positive in 73.2 % (52/71) compared with 19.7 % (14/71) in corresponding adjacent tissues, and it was associated with tumor nodules (P = 0.070), microvascular invasion (P = 0.013), Edmondson grade (P = 0.003), tumor capsula (P = 0.038) and TNM stage (P = 0.000); besides, tumors with PN-positive group expressed higher VEGF (82.7 vs. 26.3 %, χ (2) = 20.195, P = 0.000) and had higher MVD (80.5 ± 36.5 vs. 24.0 ± 19.9, t = -6.395, P = 0.000) than those in PN-negative group. Kaplan-Meier method was used for survival analysis, and Cox regression model was performed for multivariate survival analysis. In particular, the expression of PN was found to be an independent factor for predicting overall and disease-free survival of HCC. It is possible that the expression level of PN in HCC is associated with tumor metastatic potential and angiogenesis. Its abnormal expression could be a predictive factor to anticipate HCC patient's prognosis after surgery.
authors.affiliation: Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Department of Hepatic Surgery, Anhui Provincial Hospital, Anhui Medical University, 17# Lujiang Road, Hefei 230001, People's Republic of China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Lv
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Wei-Dong
authors.initials: WD
authors.lastname: Jia
authors.forename: Qi-Kai
authors.initials: QK
authors.lastname: Sun
authors.forename: Jian-Sheng
authors.initials: JS
authors.lastname: Li
authors.forename: Jin-Liang
authors.initials: JL
authors.lastname: Ma
authors.forename: Wen-Bin
authors.initials: WB
authors.lastname: Liu
authors.forename: Hang-Cheng
authors.initials: HC
authors.lastname: Zhou
authors.forename: Yong-Sheng
authors.initials: YS
authors.lastname: Ge
authors.forename: Ji-Hai
authors.initials: JH
authors.lastname: Yu
authors.forename: Hong-Hai
authors.initials: HH
authors.lastname: Xia
authors.forename: Ge-Liang
authors.initials: GL
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D015815:Cell Adhesion Molecules / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D015815:Cell Adhesion Molecules; C512835:POSTN protein, human